2. Search Result
Search Result
Results for "

E17K

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

3

Recombinant Proteins

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19719
    Miransertib
    Maximum Cited Publications
    17 Publications Verification

    ARQ-092

    		 Akt Parasite Infection Cancer
    Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib is effective against Leishmania .
    Miransertib
  • HY-176299
    Tanerasertib

    		Akt Cancer
    Tanerasertib (Compound 456) is an AKT1 inhibitor, targerting to AKT1 E17K with the EC50 of 15-60 nM. Tanerasertib can be used in the study of cancer .
    Tanerasertib
  • HY-137458A
    Vevorisertib trihydrochloride
    1 Publications Verification

    ARQ 751 trihydrochloride

    		 Akt Cancer
    Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer .
    Vevorisertib trihydrochloride
  • HY-19719A
    Miransertib hydrochloride
    Maximum Cited Publications
    17 Publications Verification

    ARQ-092 hydrochloride

    		 Akt Parasite Infection Cancer
    Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib hydrochloride is effective against Leishmania .
    Miransertib hydrochloride
  • HY-173155
    AKT1-IN-9

    		Akt Cancer
    AKT1-IN-9 (4) is a selective mutant AKT1(E17K) inhibitor, with EC50 values of 9 nM and 995 nM in LAPC4-CR and SkBr3 cells, respectively .
    AKT1-IN-9
  • HY-E70786
    AKT1 E17K Recombinant Human Active Protein Kinase

    		Akt Cancer
    AKT is the oncogenic protein kinase that regulates essential cellular functions such as migration, proliferation, differentiation, apoptosis, and metabolism. Mammalian cells are characterized by the expression of three different Akt isoforms, Akt1, Akt2, and Akt3. AKT1 E17K is a mutant of AKT1. AKT1 E17K Recombinant Human Active Protein Kinase is obtained by expressing AKT1 E17K proteins .
    AKT1 E17K Recombinant Human Active Protein Kinase
  • HY-161438
    Akt1-IN-3

    		Akt Cancer
    Akt1-IN-3 (Compd 7) is an inhibitor of AKT1. Akt1-IN-3 inhibits AKT1- E17K with IC50 < 15 nM .
    Akt1-IN-3
  • HY-161439
    Akt1-IN-4

    		Akt Cancer
    Akt1-IN-4 (Compound 62) is an AKT1-E17K inhibitor with an IC50 value of less than 15 nM .
    Akt1-IN-4
  • HY-19719B
    Miransertib mesylate

    ARQ-092 mesylate

    		 Akt Parasite Infection Cancer
    Miransertib (ARQ-092) mesylate is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib mesylate is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib mesylate is effective against Leishmania .
    Miransertib mesylate
  • HY-183124
    AKT1-IN-12

    		Akt Cancer
    AKT1-IN-12 is a AKT1 inhibitor. AKT1-IN-12 is applicable to research related to breast cancer, colorectal cancer and meningioma .
    AKT1-IN-12

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: